C.Q.Pharmaceutical Holding Co.Ltd(000950) announced on the evening of January 6 that in order to optimize the asset liability structure of the company’s holding subsidiary Chongqing pharmaceutical (Group) Co., Ltd. (hereinafter referred to as “Chongqing pharmaceutical Co., Ltd.”), further enhance the capital strength, promote the rapid development of business and ensure the realization of strategic objectives, the company invested 400 million yuan in cash to increase its capital. After the capital increase, the shareholding ratio of C.Q.Pharmaceutical Holding Co.Ltd(000950) became 99.95%. After receiving the capital increase fund, Chongqing pharmaceutical Co., Ltd. plans to use it for daily operation.
According to the announcement, as of December 31, 2020, the audited total assets of heavy Pharmaceutical Co., Ltd. were RMB 41.533 billion, the net assets were RMB 9.019 billion, and the asset liability ratio was 78.28%; As of September 30, 2021, the asset liability ratio was 79.38%. From January to September 2021, the operating revenue of heavy Pharmaceutical Co., Ltd. was 46.219 billion yuan, with a year-on-year increase of 51.96%. With the rapid growth of sales revenue, it brought a large demand for working capital.
Recently, Chongqing pharmaceutical Co., Ltd. has completed the industrial and commercial registration procedures for capital increase and obtained the business license renewed by Chongqing market supervision and Administration Bureau.
(China Securities Journal)
